Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.304
Filtrar
Añadir filtros

Intervalo de año
3.
BMC Bioinformatics ; 21(1): 313, 2020 Jul 16.
Artículo en Inglés | MEDLINE | ID: covidwho-654551

RESUMEN

BACKGROUND: Drug repurposing aims to detect the new therapeutic benefits of the existing drugs and reduce the spent time and cost of the drug development projects. The synthetic repurposing of drugs may prove to be more useful than the single repurposing in terms of reducing toxicity and enhancing efficacy. However, the researchers have not given it serious consideration. To address the issue, a novel datamining method is introduced and applied to repositioning of drugs for hypertension (HT) which is a serious medical condition and needs some improved treatment plans to help treat it. RESULTS: A novel two-step data mining method, which is based on the If-Then association rules as well as a novel discrete optimization algorithm, was introduced and applied to the synthetic repurposing of drugs for HT. The required data were also extracted from DrugBank, KEGG, and DrugR+ databases. The findings indicated that based on the different statistical criteria, the proposed method outperformed the other state-of-the-art approaches. In contrast to the previously proposed methods which had failed to discover a list on some datasets, our method could find a combination list for all of them. CONCLUSION: Since the proposed synthetic method uses medications in small dosages, it might revive some failed drug development projects and put forward a suitable plan for treating different diseases such as COVID-19 and HT. It is also worth noting that applying efficient computational methods helps to produce better results.


Asunto(s)
Antihipertensivos/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Minería de Datos , Reposicionamiento de Medicamentos , Neumonía Viral/tratamiento farmacológico , Algoritmos , Betacoronavirus , Bases de Datos Factuales , Humanos , Aprendizaje Automático , Pandemias
4.
Signal Transduct Target Ther ; 5(1): 125, 2020 07 13.
Artículo en Inglés | MEDLINE | ID: covidwho-654479

RESUMEN

Stress proteins (SPs) including heat-shock proteins (HSPs), RNA chaperones, and ER associated stress proteins are molecular chaperones essential for cellular homeostasis. The major functions of HSPs include chaperoning misfolded or unfolded polypeptides, protecting cells from toxic stress, and presenting immune and inflammatory cytokines. Regarded as a double-edged sword, HSPs also cooperate with numerous viruses and cancer cells to promote their survival. RNA chaperones are a group of heterogeneous nuclear ribonucleoproteins (hnRNPs), which are essential factors for manipulating both the functions and metabolisms of pre-mRNAs/hnRNAs transcribed by RNA polymerase II. hnRNPs involve in a large number of cellular processes, including chromatin remodelling, transcription regulation, RNP assembly and stabilization, RNA export, virus replication, histone-like nucleoid structuring, and even intracellular immunity. Dysregulation of stress proteins is associated with many human diseases including human cancer, cardiovascular diseases, neurodegenerative diseases (e.g., Parkinson's diseases, Alzheimer disease), stroke and infectious diseases. In this review, we summarized the biologic function of stress proteins, and current progress on their mechanisms related to virus reproduction and diseases caused by virus infections. As SPs also attract a great interest as potential antiviral targets (e.g., COVID-19), we also discuss the present progress and challenges in this area of HSP-based drug development, as well as with compounds already under clinical evaluation.


Asunto(s)
Antivirales/farmacología , Betacoronavirus/efectos de los fármacos , Infecciones por Coronavirus/tratamiento farmacológico , Proteínas de Choque Térmico/genética , Ribonucleoproteínas Nucleares Heterogéneas/genética , Interacciones Huésped-Patógeno/efectos de los fármacos , Neumonía Viral/tratamiento farmacológico , Antivirales/síntesis química , Betacoronavirus/genética , Betacoronavirus/patogenicidad , Ensamble y Desensamble de Cromatina/efectos de los fármacos , Infecciones por Coronavirus/genética , Infecciones por Coronavirus/patología , Infecciones por Coronavirus/virología , Regulación de la Expresión Génica , Proteínas de Choque Térmico/agonistas , Proteínas de Choque Térmico/antagonistas & inhibidores , Proteínas de Choque Térmico/metabolismo , Ribonucleoproteínas Nucleares Heterogéneas/agonistas , Ribonucleoproteínas Nucleares Heterogéneas/antagonistas & inhibidores , Ribonucleoproteínas Nucleares Heterogéneas/metabolismo , Interacciones Huésped-Patógeno/genética , Humanos , Terapia Molecular Dirigida/métodos , Pandemias , Neumonía Viral/genética , Neumonía Viral/patología , Neumonía Viral/virología , ARN Polimerasa II/genética , ARN Polimerasa II/metabolismo , Precursores del ARN/genética , Precursores del ARN/metabolismo , Índice de Severidad de la Enfermedad , Transducción de Señal , Transcripción Genética/efectos de los fármacos , Replicación Viral/efectos de los fármacos
6.
Nat Commun ; 11(1): 2750, 2020 06 02.
Artículo en Inglés | MEDLINE | ID: covidwho-680538

RESUMEN

Influenza viruses annually kill 290,000-650,000 people worldwide. Antivirals can reduce death tolls. Baloxavir, the recently approved influenza antiviral, inhibits initiation of viral mRNA synthesis, whereas oseltamivir, an older drug, inhibits release of virus progeny. Baloxavir blocks virus replication more rapidly and completely than oseltamivir, reducing the duration of infectiousness. Hence, early baloxavir treatment may indirectly prevent transmission. Here, we estimate impacts of ramping up and accelerating baloxavir treatment on population-level incidence using a new model that links viral load dynamics from clinical trial data to between-host transmission. We estimate that ~22 million infections and >6,000 deaths would have been averted in the 2017-2018 epidemic season by administering baloxavir to 30% of infected cases within 48 h after symptom onset. Treatment within 24 h would almost double the impact. Consequently, scaling up early baloxavir treatment would substantially reduce influenza morbidity and mortality every year. The development of antivirals against the SARS-CoV2 virus that function like baloxavir might similarly curtail transmission and save lives.


Asunto(s)
Antivirales/uso terapéutico , Epidemias , Gripe Humana/tratamiento farmacológico , Orthomyxoviridae/efectos de los fármacos , Oxazinas/uso terapéutico , Piridinas/uso terapéutico , Tiepinas/uso terapéutico , Triazinas/uso terapéutico , Antivirales/farmacología , Betacoronavirus/efectos de los fármacos , Proliferación Celular , Infecciones por Coronavirus/tratamiento farmacológico , Humanos , Gripe Humana/virología , Oseltamivir/farmacología , Oseltamivir/uso terapéutico , Oxazinas/farmacología , Pandemias , Neumonía Viral/tratamiento farmacológico , Salud Pública , Piridinas/farmacología , ARN Mensajero/metabolismo , Estaciones del Año , Tiepinas/farmacología , Triazinas/farmacología , Carga Viral , Replicación Viral/efectos de los fármacos
7.
JAMA Netw Open ; 3(7): e2013880, 2020 07 01.
Artículo en Inglés | MEDLINE | ID: covidwho-621959

RESUMEN

Importance: During the ongoing coronavirus disease 2019 pandemic, case reports have suggested that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may lead to adverse outcomes. Objective: To study the association of NSAID use with adverse outcomes in patients hospitalized with influenza or influenza pneumonia. Design, Setting, and Participants: This cohort study used propensity score matching among 7747 individuals aged 40 years or older who were hospitalized with influenza, confirmed by polymerase chain reaction or antigen testing, between 2010 and 2018. Data were collected using Danish nationwide registers. All analyses reported were performed on May 29, 2020. Exposures: Prescription fill of an NSAID within 60 days before admission. Main Outcomes and Measures: Risk ratio (RR) and risk difference (RD) with 95% CIs for intensive care unit admission and death within 30 days of admission. Results: A total of 7747 patients (median [interquartile range] age, 71 [59-80] years, 3980 [51.4%] men) with confirmed influenza were identified. Of these, 520 (6.7%) were exposed to NSAIDs. In the unmatched cohorts, 104 of 520 patients (20.0%) who used NSAIDs and 958 of 7227 patients (13.3%) who did not use NSAIDs were admitted to the intensive care unit. For death within 30 days of admission, we observed 37 events (7.1%) among those who used NSAIDs compared with 563 events (7.8%) among those who did not. Current NSAID use was associated with intensive care unit admission (RR, 1.51; 95% CI, 1.26 to 1.81; RD, 6.7%; 95% CI, 3.2% to 10.3%), while NSAID use was not associated with death (RR, 0.91; 95% CI, 0.66 to 1.26; RD, -0.7%; 95% CI, -3.0% to 1.6%). In the matched cohorts, risks were unchanged for patients who used NSAIDs, while 83 ICU admissions (16.0%) and 36 deaths (6.9%) were observed among matched individuals who did not use NSAIDs. Matched (ie, adjusted) analyses yielded attenuated risk estimates for intensive care unit admission (RR, 1.25; 95% CI, 0.95 to 1.63; RD, 4.0%; 95% CI, -0.6% to 8.7%) and death (RR, 1.03; 95% CI, 0.66 to 1.60; RD, 0.2%; 95% CI, -2.9% to 3.3%). Associations were more pronounced among patients who used NSAIDs for a longer period (eg, for intensive care unit admission: RR, 1.90; 95% CI, 1.19 to 3.06; RD, 13.4%; 95% CI, 4.0% to 22.8%). Conclusions and Relevance: In this cohort study of adult patients hospitalized with influenza, the use of NSAIDs was not associated with 30-day intensive care unit admission or death in adjusted analyses. There was an association between long-term use of NSAIDs and intensive care unit admission.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Infecciones por Coronavirus/tratamiento farmacológico , Hospitalización , Unidades de Cuidados Intensivos , Neumonía Viral/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/efectos adversos , Betacoronavirus , Estudios de Cohortes , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/virología , Dinamarca/epidemiología , Femenino , Humanos , Gripe Humana , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Pandemias , Neumonía , Neumonía Viral/complicaciones , Neumonía Viral/mortalidad , Neumonía Viral/virología
8.
Pol Arch Intern Med ; 130(5): 420-430, 2020 05 29.
Artículo en Inglés | MEDLINE | ID: covidwho-621657

RESUMEN

The outbreak of the coronavirus disease 2019 (COVID­19) pandemic has become the biggest challenge for the whole human community since many years. It seems that the proper identification of all people infected with severe acute respiratory syndrome coronavirus 2 (SARS­CoV­2) is the best strategy to limit the transmission. However, in a significant proportion of patients, there are no clinical manifestations of the disease, and symptoms may be very mild or atypical. There is a growing body of evidence that digestive manifestations of COVID­19 are frequently reported and may precede typical respiratory symptoms. Moreover, SARS­CoV­2 particles were found in the gastrointestinal epithelial cells, and viral RNA was detected in the feces of patients with COVID­19. These data suggest that gastrointestinal symptoms in COVID­19 are not accidental findings and they may result from direct digestive involvement. Patients with new­onset diarrhea, abdominal pain, nausea, and vomiting without any other evident etiological factors should be tested for SARS­CoV­2 infection. Gastroenterologists and members of other medical specialties should also remember that the current epidemiological situation has changed diagnostic and therapeutic algorithms in the management of several gastrointestinal and liver disorders. This review article summarizes the currently available data on multiple gastroenterological aspects of COVID­19 and provides information on practical recommendations and position statements of the most prominent associations in the field of gastroenterology, which appeared in response to the emergence of the pandemic.


Asunto(s)
Betacoronavirus/metabolismo , Infecciones por Coronavirus/complicaciones , Enfermedades del Sistema Digestivo/virología , Sistema Digestivo/virología , Neumonía Viral/complicaciones , Coronavirus/metabolismo , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/terapia , Sistema Digestivo/metabolismo , Humanos , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/terapia
9.
Mol Diagn Ther ; 24(3): 251-262, 2020 06.
Artículo en Inglés | MEDLINE | ID: covidwho-634822

RESUMEN

This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in Covid-19), administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory anti-inflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.


Asunto(s)
Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Terapia Molecular Dirigida/métodos , Biomarcadores/sangre , Ácidos Nucleicos Libres de Células/sangre , Enfermedad Crónica , Infecciones por Coronavirus/tratamiento farmacológico , Proteína HMGB1/sangre , Homeostasis , Humanos , Inmunidad Innata/efectos de los fármacos , Inmunidad Innata/fisiología , Patrón Molecular Asociado a Patógenos/metabolismo , Proteínas S100/sangre , Vacunación
10.
ACS Chem Neurosci ; 11(15): 2145-2148, 2020 08 05.
Artículo en Inglés | MEDLINE | ID: covidwho-646274

RESUMEN

Studies have shown that the calcium ion (Ca2+) plays important roles both in Alzheimer's dementia and SARS-CoV S-mediated fusion to host cell entry. An elevated level of intracellular calcium causes neuronal dysfunction, cell death, and apoptosis. Dysregulation of calcium has also been shown to increase the production of amyloid beta (Aß) protein, the hallmark of Alzheimer's dementia. Reversely, deposition of Aß is also responsible for calcium dysregulation. On the other hand, it has been well investigated that viruses can disturb host cell Ca2+ homeostasis as well as modulate signal transduction mechanisms. Viruses can also hijack the host cell calcium channels and pumps to release more intracellular Ca2+ to utilize for their life cycle. Even though evidence has not been reported on SARS-CoV-2 concerning Ca2+ regulation, however, it has been well established that Ca2+ is essential for viral entry, viral gene replication, and virion maturation and release. Recent reports suggest that SARS-CoV needs two Ca2+ ions to fuse with the host cell at the entry step. Furthermore, some calcium channel blockers (CCBs), such as nimodipine, memantine, etc., have been reported to be effective in the treatment of dementia in Alzheimer's disease (AD) as well as have shown inhibition in various virus infections.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Betacoronavirus , Bloqueadores de los Canales de Calcio/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Neumonía Viral/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/psicología , Calcio/metabolismo , Bloqueadores de los Canales de Calcio/química , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio/metabolismo , Infecciones por Coronavirus/metabolismo , Infecciones por Coronavirus/psicología , Humanos , Pandemias , Neumonía Viral/metabolismo , Neumonía Viral/psicología , Resultado del Tratamiento
11.
Rheumatol Int ; 40(9): 1353-1360, 2020 09.
Artículo en Inglés | MEDLINE | ID: covidwho-640396

RESUMEN

As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence regarding the risk and outcome of COVID-19 in patients with systemic autoimmune diseases. Thus far there is no convincing evidence that any disease-modifying anti-rheumatic drug (conventional synthetic, biologic or targeted synthetic) including hydroxychloroquine, may protect against severe COVID-19 infection; answers about their possible usefulness in the management of the cytokine storm associated with severe COVID-9 infection will only arise from ongoing randomized controlled trials. Evidence on COVID-19 risk and outcome in patients with systemic autoimmune diseases is extremely limited; thus, any conclusions would be unsafe and should be seen with great caution. At present, the risk and severity (hospitalization, intensive care unit admission and death) of COVID-19 infection in people with autoimmune diseases do not appear particularly dissimilar to the general population, with the possible exception of hospitalization in patients exposed to high glucocorticoid doses. At this stage it is impossible to draw any conclusions for differences in COVID-19 risk and outcome between different autoimmune diseases and between the various immunomodulatory therapies used for them. More research in the field is obviously required, including as a minimum careful and systematic epidemiology and appropriately controlled clinical trials.


Asunto(s)
Antirreumáticos/uso terapéutico , Enfermedades Autoinmunes/tratamiento farmacológico , Infecciones por Coronavirus/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Neumonía Viral/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Enfermedades Autoinmunes/epidemiología , Enfermedades Autoinmunes/inmunología , Betacoronavirus , Comorbilidad , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Síndrome de Liberación de Citoquinas/inmunología , Humanos , Inhibidores de las Cinasas Janus/uso terapéutico , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Inhibidores del factor de Necrosis Tumorales/uso terapéutico
12.
Int J Immunogenet ; 47(4): 319-323, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: covidwho-640248

RESUMEN

Susceptibility to viral infection, development of immunity, response to treatment and patient clinical outcomes are all under the control of heritable factors in the host. In the context of the current SARS-Cov-2 pandemic, this review considers existing immunogenetic knowledge of virus-immune system interactions. A major focus is to highlight areas in which work is required in order to improve understanding of antiviral immune responses and to move towards improved patient management.


Asunto(s)
Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/patología , Síndrome de Liberación de Citoquinas/inmunología , Inmunidad Innata/inmunología , Neumonía Viral/inmunología , Neumonía Viral/patología , Betacoronavirus/inmunología , Infecciones por Coronavirus/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/patología , Susceptibilidad a Enfermedades/inmunología , Humanos , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Pandemias , Neumonía Viral/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/metabolismo
13.
Int Immunopharmacol ; 86: 106760, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-634138

RESUMEN

Due to the vastness of the science virology, it is no longer an offshoot solely of the microbiology. Viruses have become as the causative agents of major epidemics throughout history. Many therapeutic strategies have been used for these microorganisms, and in this way the recognizing of potential targets of viruses is of particular importance for success. For decades, antibodies and antibody fragments have occupied a significant body of the treatment approaches against infectious diseases. Because of their high affinity, they can be designed and engineered against a variety of purposes, mainly since antibody fragments such as scFv, nanobody, diabody, and bispecific antibody have emerged owing to their small size and interesting properties. In this review, we have discussed the antibody discovery and molecular and biological design of antibody fragments as inspiring therapeutic and diagnostic agents against viral targets.


Asunto(s)
Anticuerpos Antivirales/uso terapéutico , Betacoronavirus/inmunología , Productos Biológicos/uso terapéutico , Infecciones por Coronavirus/tratamiento farmacológico , Neumonía Viral/tratamiento farmacológico , Animales , Anticuerpos Biespecíficos/inmunología , Anticuerpos Biespecíficos/uso terapéutico , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Antivirales/inmunología , Productos Biológicos/inmunología , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/virología , Modelos Animales de Enfermedad , Diseño de Fármacos , Descubrimiento de Drogas , Humanos , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/inmunología , Neumonía Viral/virología , Anticuerpos de Dominio Único/inmunología , Anticuerpos de Dominio Único/uso terapéutico
14.
Biomed Res Int ; 2020: 1594726, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-633800

RESUMEN

Acute kidney injury (AKI) is a common complication of sepsis and has also been observed in some patients suffering from the new coronavirus pneumonia COVID-19, which is currently a major global concern. Thymoquinone (TQ) is one of the most active ingredients in Nigella sativa seeds. It has a variety of beneficial properties including anti-inflammatory and antioxidative activities. Here, we investigated the possible protective effects of TQ against kidney damage in septic BALB/c mice. Eight-week-old male BALB/c mice were divided into four groups: control, TQ, cecal ligation and puncture (CLP), and TQ+CLP. CLP was performed after 2 weeks of TQ gavage. After 48 h, we measured the histopathological alterations in the kidney tissue and the serum levels of creatinine (CRE) and blood urea nitrogen (BUN). We also evaluated pyroptosis (NLRP3, caspase-1), apoptosis (caspase-3, caspase-8), proinflammatory (TNF-α, IL-1ß, and IL-6)-related protein and gene expression levels. Our results demonstrated that TQ inhibited CLP-induced increased serum CRE and BUN levels. It also significantly inhibited the high levels of NLRP3, caspase-1, caspase-3, caspase-8, TNF-α, IL-1ß, and IL-6 induced by CLP. Furthermore, NF-κB protein level was significantly decreased in the TQ+CLP group than in the CLP group. Together, our results indicate that TQ may be a potential therapeutic agent for sepsis-induced AKI.


Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/etiología , Benzoquinonas/uso terapéutico , Sepsis/complicaciones , Sepsis/tratamiento farmacológico , Lesión Renal Aguda/patología , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Antioxidantes/uso terapéutico , Apoptosis/efectos de los fármacos , Betacoronavirus , Nitrógeno de la Urea Sanguínea , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/tratamiento farmacológico , Creatinina/sangre , Citocinas/metabolismo , Modelos Animales de Enfermedad , Humanos , Mediadores de Inflamación/metabolismo , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Masculino , Ratones , Ratones Endogámicos BALB C , FN-kappa B/metabolismo , Pandemias , Neumonía Viral/complicaciones , Neumonía Viral/tratamiento farmacológico
15.
Nano Lett ; 20(7): 5367-5375, 2020 07 08.
Artículo en Inglés | MEDLINE | ID: covidwho-628240

RESUMEN

Geometry-matching has been known to benefit the formation of stable biological interactions in natural systems. Herein, we report that the spiky nanostructures with matched topography to the influenza A virus (IAV) virions could be used to design next-generation advanced virus inhibitors. We demonstrated that nanostructures with spikes between 5 and 10 nm bind significantly better to virions than smooth nanoparticles, due to the short spikes inserting into the gaps of glycoproteins of the IAV virion. Furthermore, an erythrocyte membrane (EM) was coated to target the IAV, and the obtained EM-coated nanostructures could efficiently prevent IAV virion binding to the cells and inhibit subsequent infection. In a postinfection study, the EM-coated nanostructures reduced >99.9% virus replication at the cellular nontoxic dosage. We predict that such a combination of geometry-matching topography and cellular membrane coating will also push forward the development of nanoinhibitors for other virus strains, including SARS-CoV-2.


Asunto(s)
Betacoronavirus/ultraestructura , Infecciones por Coronavirus/virología , Nanoestructuras/ultraestructura , Neumonía Viral/virología , Antivirales/farmacología , Betacoronavirus/efectos de los fármacos , Sitios de Unión , Infecciones por Coronavirus/tratamiento farmacológico , Diseño de Fármacos , Humanos , Virus de la Influenza A/efectos de los fármacos , Virus de la Influenza A/ultraestructura , Microscopía Electrónica , Modelos Biológicos , Nanotecnología , Pandemias , Neumonía Viral/tratamiento farmacológico , Glicoproteína de la Espiga del Coronavirus/efectos de los fármacos , Glicoproteína de la Espiga del Coronavirus/ultraestructura , Internalización del Virus/efectos de los fármacos
16.
Medicine (Baltimore) ; 99(31): e21310, 2020 Jul 31.
Artículo en Inglés | MEDLINE | ID: covidwho-702282

RESUMEN

BACKGROUND: Since December 2019, there have been many cases of viral pneumonia of unknown causes in Wuhan City, Hubei Province. During the period of novel coronavirus, according to the observation of limited autopsy and biopsy pathological results, pulmonary interstitial fibrosis appeared in some pathological changes of lung. Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial pneumonia with unknown etiology and pathological changes limited to the lung. At present, there is still a lack of reevaluation of systematic evaluation of traditional Chinese medicine treatment IPF. Therefore, a systematic re-evaluation of the systematic evaluation of traditional Chinese medicine in the treatment of pulmonary fibrosis may help to understand the effective treatment scheme of traditional Chinese medicine in the treatment of pulmonary fibrosis and provide more reliable evidence for the first-line clinicians to treat novel coronavirus. METHODS: We will search 3 foreign electronic databases (Cochrane Library, Embase, PubMed) and 4 Chinese electronic databases (China National Knowledge Infrastructure [CNKI], WangFang Database, Chinese Biomedical Literature Database [CBM], and Chinese Scientific Journal Database [VIP]) to collect potential systematic reviews from their inceptions to February 2020. The language of publication is limited to Chinese or English. We will consider SRs and meta-analysis of Traditional Chinese Medicine for the Treatment of pulmonary fibrosis. Two reviewers will identify relevant studies, and then assess the methodological quality by assessment of multiple systematic reviews-2 tool. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) report checklist to assess the quality of reports included in the study. In order to better evaluate the systematic evaluation included in this research, risk of bias in systematic review tool is included in this research to evaluate the methodological quality. The quality of evidence of the included systematic reviews was assessed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. The Primary outcomes include: Clinical total effective rate, curative effect of TCM symptoms, pulmonary function and blood gas analysis. RESULTS: The results of this study will be published in a peer-reviewed journal. CONCLUSIONS: We expect to obtain reliable evidence from systematic analysis of traditional Chinese medicine treatment of pulmonary fibrosis in an available and useful document. REGISTRATION NUMBER: INPLASY202060029.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Medicina China Tradicional/métodos , Neumonía Viral/tratamiento farmacológico , Fibrosis Pulmonar/tratamiento farmacológico , Infecciones por Coronavirus/complicaciones , Femenino , Humanos , Masculino , Metaanálisis como Asunto , Pandemias , Neumonía Viral/complicaciones , Fibrosis Pulmonar/virología , Proyectos de Investigación , Revisiones Sistemáticas como Asunto , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA